Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis Bb1
- Development stage
- Preclinical
- Lead developer
- Probiotical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis Bb1 (DSM 17850) is a specific strain of Bifidobacterium animalis subsp. lactis, a gram-positive, anaerobic, rod-shaped bacterium commonly found in the mammalian large intestine. As a probiotic, it contributes to gut health by producing lactic and acetic acids, which create an unfavorable environment for pathogenic bacteria. It also produces short-chain fatty acids like butyrate and propionate, serving as energy sources for colon cells. This strain is known for its ability to bioincorporate zinc and is utilized in nutraceutical and pharmaceutical applications, particularly for supporting healthy aging, prostate health, and gynecology and urology health. It also plays a role in immune modulation and maintaining intestinal barrier function.
- Other names
- bifidobacterium animalis spp. lactis Bi1Bifidobacterium lactis Bb1Bb1Bb-1Bb 1
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis Bb1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis Bb1.